SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-000652
Filing Date
2023-01-06
Accepted
2023-01-06 16:20:37
Documents
13
Period of Report
2023-01-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20230106_8k.htm   iXBRL 8-K 35541
  Complete submission text file 0001437749-23-000652.txt   170255

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pbla-20230103.xsd EX-101.SCH 3600
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20230103_def.xml EX-101.DEF 11531
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20230103_lab.xml EX-101.LAB 15413
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20230103_pre.xml EX-101.PRE 11687
7 EXTRACTED XBRL INSTANCE DOCUMENT pbla20230106_8k_htm.xml XML 2554
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

IRS No.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 23515335
SIC: 2834 Pharmaceutical Preparations